<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29641580</article-id><article-id pub-id-type="pmc">5894967</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0194525</article-id><article-id pub-id-type="publisher-id">PONE-D-17-42924</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Departures from Diploidy</subject><subj-group><subject>Polyploidy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Chromosome Biology</subject><subj-group><subject>Chromosomal Aberrations</subject><subj-group><subject>Chromosomal Translocations</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Histochemistry and Cytochemistry Techniques</subject><subj-group><subject>Immunohistochemistry Techniques</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Immunologic Techniques</subject><subj-group><subject>Immunohistochemistry Techniques</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Spectrum Analysis Techniques</subject><subj-group><subject>Spectrophotometry</subject><subj-group><subject>Cytophotometry</subject><subj-group><subject>Flow Cytometry</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Chromosome Biology</subject><subj-group><subject>Chromosomes</subject><subj-group><subject>Chromosome Structure and Function</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Prognosis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Specimen Preparation and Treatment</subject><subj-group><subject>Staining</subject><subj-group><subject>Chromosome Staining</subject><subj-group><subject>Giemsa Staining</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Specimen Preparation and Treatment</subject><subj-group><subject>Staining</subject><subj-group><subject>Cell Staining</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Clinicopathological analysis of polyploid diffuse large B-cell lymphoma</article-title><alt-title alt-title-type="running-head">Polyploidy and diffuse large B-cell lymphoma</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-1044-1654</contrib-id><name><surname>Shimono</surname><given-names>Joji</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Miyoshi</surname><given-names>Hiroaki</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Software</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Kiyasu</surname><given-names>Junichi</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kamimura</surname><given-names>Tomohiko</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Eto</surname><given-names>Tetsuya</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Miyagishima</surname><given-names>Takuto</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nagafuji</surname><given-names>Koji</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><xref ref-type="aff" rid="aff007"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Seto</surname><given-names>Masao</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Methodology</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Teshima</surname><given-names>Takanori</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Supervision</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ohshima</surname><given-names>Koichi</given-names></name><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Pathology, Kurume University, School of Medicine, Kurume, Japan</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department of Hematology, Iizuka hospital, Iizuka, Japan</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Department of Hematology, Harasanshin Hospital, Fukuoka, Japan</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>Department of Hematology, Kushiro Rosai Hospital, Kushiro, Japan</addr-line></aff><aff id="aff007"><label>7</label>
<addr-line>Department of Hematology, Kurume University, School of Medicine, Kurume, Japan</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Ariga</surname><given-names>Hiroyoshi</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Hokkaido Daigaku, JAPAN</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>miyoshi_hiroaki@med.kurume-u.ac.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>11</day><month>4</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>13</volume><issue>4</issue><elocation-id>e0194525</elocation-id><history><date date-type="received"><day>7</day><month>12</month><year>2017</year></date><date date-type="accepted"><day>5</day><month>3</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 Shimono et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Shimono et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0194525.pdf"/><abstract><p>Polyploid chromosomes are those with more than two sets of homologous chromosomes. Polyploid chromosomal abnormalities are observed in various malignant tumors. The prognosis in such cases is generally poor. However, there are no studies examining the prognosis of diffuse large B-cell lymphoma (DLBCL) with polyploid chromosomal abnormalities. Therefore, we statistically compared the clinicopathological features between polyploid DLBCL and DLBCL without polyploid abnormalities. Herein, 51 polyploid DLBCL and 53 control (without polyploid chromosomal abnormalities) cases were examined. G-banding method was employed to define polyploidy by cytogenetic analysis. Subsequently, flow cytometric immunophenotyping and immunohistochemical staining were performed. Polyploid DLBCL was defined as DLBCL with either near-tetraploid or greater number of chromosomes, as detected by the G-band. In a survival analysis, a significantly worse overall survival (OS) was observed for polyploid DLBCL (<italic>p</italic> = 0.04; <italic>p</italic> = 0.02 in cases who received R-CHOP regimens). In a multivariate analysis of OS, polyploid chromosomal abnormalities were an independent prognostic factor. Our results suggest that polyploid chromosomal abnormalities detected through G-band may represent a new poor prognostic factor for DLBCL.</p></abstract><funding-group><funding-statement>The authors received no specific funding for this work.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="4"/><page-count count="13"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>A portion of the data have been uploaded as a Supporting Information file. However, further data sharing has been restricted by the UK Twins Research Executive Committee (TREC, at King&#x02019;s College London) because the data contain potentially identifying information. To request data access, please contact Victoria Vasquez of the UK Twins Research Executive Committee (TREC, at King&#x02019;s College London) at <email>victoria.vazquez@kcl.ac.uk</email>.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>A portion of the data have been uploaded as a Supporting Information file. However, further data sharing has been restricted by the UK Twins Research Executive Committee (TREC, at King&#x02019;s College London) because the data contain potentially identifying information. To request data access, please contact Victoria Vasquez of the UK Twins Research Executive Committee (TREC, at King&#x02019;s College London) at <email>victoria.vazquez@kcl.ac.uk</email>.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Diffuse large B-cell lymphoma (DLBCL) is the most frequent type of B-cell lymphoma, accounting for 30%-40% of non-Hodgkin&#x02019;s lymphoma [<xref rid="pone.0194525.ref001" ref-type="bibr">1</xref>]. The biological properties, genetic mutations, immune phenotypes, and cell morphology of DLBCL are varied, and therefore, DLBCL is considered a heterogeneous group [<xref rid="pone.0194525.ref002" ref-type="bibr">2</xref>]. Chromosomal translocation of immunoglobulin genes, such as <italic>c-MYC</italic> and <italic>BCL2</italic>, are widely observed as chromosomal abnormalities in DLBCL. In addition, these chromosomal translocations are associated with poor prognosis in DLBCL [<xref rid="pone.0194525.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0194525.ref004" ref-type="bibr">4</xref>].</p><p>Polyploidy refers to the existence of more than two sets of homologous chromosomes within a cell. Abnormalities in the cell cycle, re-replication of DNA, and cell division are some factors that cause polyploidy [<xref rid="pone.0194525.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0194525.ref006" ref-type="bibr">6</xref>]. In normal tissue, chromosome polyploidization can be observed in placental trophoblasts and megakaryocytes during the differentiation process. Polyploid chromosomal abnormalities are also seen in 6.9% of malignant tumors, and are associated with poor prognosis in acute myeloid leukemia, breast cancer, ovarian cancer, and colon cancer [<xref rid="pone.0194525.ref007" ref-type="bibr">7</xref>&#x02013;<xref rid="pone.0194525.ref010" ref-type="bibr">10</xref>].</p><p>We had previously examined the histological features of 16 cases of DLBCL in which polyploid chromosomal abnormalities were observed by using the G-band method [<xref rid="pone.0194525.ref011" ref-type="bibr">11</xref>]. DLBCL with polyploid chromosomal abnormalities was observed in 2.9% of the cases. Unique histological characteristics, Hodgkin&#x02019;s-like giant cells and multilobated cells, were observed in polyploid DLBCL [<xref rid="pone.0194525.ref011" ref-type="bibr">11</xref>]. However, to the best of our knowledge, there are no studies comparing the clinicopathological features between polyploid DLBCL and DLBCL without polyploid chromosomal abnormalities.</p><p>Therefore, in the present study, we statistically compared the clinicopathological features between polyploid DLBCL and DLBCL without polyploid abnormalities.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and methods</title><sec id="sec003"><title>Patients and tissue samples</title><p>We reviewed 51 cases of polyploid DLBCL, not otherwise specified (NOS) from 2008 to 2014 in the Department of Pathology, Kurume University. The karyotypes of the polyploid DLBCL cases are shown in <xref ref-type="supplementary-material" rid="pone.0194525.s003">S1 Table</xref>. Additionally, 53 cases of DLBCL, NOS were extracted as control cases from our previous study [<xref rid="pone.0194525.ref012" ref-type="bibr">12</xref>]. The control cases did not have polyploid abnormalities, validated by using the G-banding method (<xref ref-type="supplementary-material" rid="pone.0194525.s004">S2 Table</xref>). Paraffin-embedded tissues were used for diagnosis and immunohistochemical staining (IHS). All cases were reviewed by experienced hematopathologists (OK and MH) and were diagnosed according to the World Health Organization (WHO) classification [<xref rid="pone.0194525.ref013" ref-type="bibr">13</xref>]. The use of materials and clinical information were approved by the Research Ethics Committee of Kurume University and were in accordance with the Declaration of Helsinki. All data were fully anonymized.</p></sec><sec id="sec004"><title>Definition of polyploidy in cytogenetic analysis</title><p>The G-banding method was performed for cytogenetic analysis. Karyotypes were reviewed according to the International System for Human Cytogenetics Nomenclature (ISCN 2013). We defined DLBCL cases with near-tetraploid or greater number of chromosomes as polyploid DLBCL as per our previous study [<xref rid="pone.0194525.ref011" ref-type="bibr">11</xref>]. According to ISCN 2013, chromosomal numbers of 81&#x02013;103 was defined as near-tetraploid and chromosomal numbers of 104&#x02013;126 was defined as near-pentaploid, while DLBCL with a chromosomal number of &#x0003e;127 was not observed in this study.</p></sec><sec id="sec005"><title>Flow cytometric immunophenotyping analysis</title><p>For flow cytometric immunophenotyping analysis, unfixed tissues were pulverized to prepare a cell suspension. The samples were centrifuged at 1800 rpm for 5 min, and washed with 5 mL of 10% phosphate-buffered saline (PBS) after discarding the suspension twice. The cells were then resuspended with CD45 (J.33; Becton-Dickinson, Mountain View, CA, USA) and then with the other antibodies as follows at 4&#x000b0;C for 30 min. The hemolytic agents were then added, and the samples were centrifuged again at 1800 rpm for 5 min, and then washed with 5 mL of 10% PBS after discarding the suspension twice. Flow cytometric immunophenotyping analysis was then performed with a flow cytometer (FACS-Calibur, Becton-Dickinson) and the data were analyzed with the Cell Quest software program (Becton-Dickinson). The cells were gated according to forward scatter (FSC) and side scatter (SSC), and tumor cells were further gated according to CD45 and SSC. The gated area with tumor cells was then analyzed by fluorescein isothiocyanate (FITC) and phycoerythrin (PE) detection conjugated to the antibodies for the relevant markers. Information of the antibodies is summarized in <xref ref-type="supplementary-material" rid="pone.0194525.s005">S3 Table</xref>. Evaluation of live cells was conducted using propidium iodide (PI) staining (500 &#x003bc;g/mL). Mouse IgG1-FITC (Becton-Dickinson) and Mouse IgG1-PE (Becton-Dickinson) were used as negative controls.</p></sec><sec id="sec006"><title>Immunohistochemical staining</title><p>Immunohistochemical staining (IHC) was carried out using 2.5-&#x003bc;m-thick, formalin-fixed, paraffin-embedded tissue sections for all cases. The slides were deparaffinized with xylene followed by ethanol. After rehydration with water, antigen retrieval was performed with antibody-specific buffer in a microwave oven. Endogenous peroxidase activity was blocked by incubating in 3% hydrogen peroxide for 5 min. The slides were then incubated with each antibody and EnVision1 System horseradish peroxide-labeled anti-mouse polymer (Dakocytomation) for 30 min. Visualization was performed using diaminobenzidine for 5 min. The slides were counterstained with hematoxylin, dehydrated with ethanol, and mounted under coverslips. Information of the antibodies is provided in <xref ref-type="supplementary-material" rid="pone.0194525.s005">S3 Table</xref>. If &#x0003e;30% of the neoplastic cells were immunostained (except for p53 staining), the case was defined as positive. According to the results of a previous study, only cases showing a strong immunostaining intensity, in which the anti-p53 antibody immunostained &#x0003e; 50% of the neoplastic cells, were defined as p53-positive [<xref rid="pone.0194525.ref014" ref-type="bibr">14</xref>]. When CD5-positive DLBCL was detected, cyclin D1 (SP4) (ThermoScientific, Runcorn, UK) staining was performed to exclude mantle cell lymphoma, an aggressive variant.</p></sec><sec id="sec007"><title>Quantification of various markers in CD20-positive tumor cells</title><p>The positive ratios of several markers (CD5, CD10, CD30, BCL2, BCL6, and MUM1) were examined for the CD20-positive tumor cells using flow cytometry (CD5, CD10, and CD30) and IHC (BCL2, BCL6, and MUM1). The proportion of cells positive for each marker was divided by the CD20-positive cell ratio in the gated area of tumor cells (for flow cytometry) or positive tumor cells (for IHC).</p></sec><sec id="sec008"><title><italic>In situ</italic> hybridization for Epstein-Barr virus (EBV)-encoded RNA</title><p>EBV was detected by <italic>in situ</italic> hybridization with a fluorescein-conjugated EBV peptide nuclei acid (PNA) probe kit (Dakocytomation) according to the manufacturer&#x02019;s instructions. This probe was complementary to the two nuclear EBER RNAs encoded by EBV. If &#x0003e;30% of the neoplastic cells were immunostained, the case was defined as positive.</p></sec><sec id="sec009"><title>Fluorescence in situ hybridization (FISH) analysis</title><p>The following probes were used for FISH analysis according to previously published protocols [<xref rid="pone.0194525.ref015" ref-type="bibr">15</xref>, <xref rid="pone.0194525.ref016" ref-type="bibr">16</xref>]: <italic>MYC</italic> FISH DNA Probe; Split Signal (Abbott Molecular, Abbott Park, IL, USA); the Vysis LSI <italic>IGH</italic>/<italic>BCL2</italic> Dual Color, Dual Fusion Translocation Probe (Abbott Molecular); and the Vysis LSI <italic>BCL6</italic> Dual Color Break Apart Rearrangement Probe (Abbott Molecular). Shortly after deparaffinization and dehydration, the specimens were incubated in 2X saline-sodium citrate (SSC) buffer at 80&#x000b0;C for 30 min and digested with protease (25&#x02013;28&#x000b0;C, 10 min). After post-fixation and dehydration, the probe was applied to the slide under a coverslip and left to hybridize (95&#x000b0;C, 5 min; 37&#x000b0;C, 16 h). Hybridized slides were washed and air-dried before counterstaining with 4&#x02032;,6-diamidino-2 phenylindole (DAPI) for fluorescence microscopy analysis. The cut-off values for positivity were the presence of signals in 1% of cells in a cell suspension and in 5% of cells, based on laboratory-established thresholds.</p></sec><sec id="sec010"><title>Statistical analysis</title><p>Clinicopathological characteristics of the patients were compared by using the chi-squared test or Fisher&#x02019;s two-sided exact test, as needed. The end-point of overall survival (OS) was defined as the time of death due to DLBCL. The end-point of progression free survival (PFS) was defined as the time of relapse due to DLBCL. Survival curves of OS and PFS were calculated using the Kaplan&#x02013;Meier method. A log-rank test was used to compare survival curves. Univariate and multivariate Cox proportional regression models were used to evaluate the proposed prognostic factors. <italic>P</italic> &#x0003c; 0.05 was considered statistically significant. JMP version 11.0 was used in all analyses.</p></sec></sec><sec sec-type="results" id="sec011"><title>Results</title><sec id="sec012"><title>Clinicopathological properties</title><p>We investigated a comparison with control DLBCL to clarify the clinicopathological properties of polyploid DLBCL. <xref ref-type="table" rid="pone.0194525.t001">Table 1</xref> shows the clinical features of the polyploid DLBCL and control DLBCL cases. No significant differences were observed between the two groups with respect to age, sex, performance status (PS), number of extranodal infiltration sites &#x0003e; 1, B symptoms, lactate dehydrogenase elevation, or advanced stage. Further, no significant differences were observed between the groups with respect to known poor prognostic factors, including the International Prognostic Index (IPI). <xref ref-type="table" rid="pone.0194525.t002">Table 2</xref> shows the clinical outcomes and therapy of the two case groups. No significant difference was noted between the two groups with respect to the treatment strategy and response to initial therapy. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or an R-CHOP-like regimen was carried out in 88.2% of the polyploid DLBCL cases (45/51) and in 79.2% (42/53) of the control DLBCL cases, with no significant difference (<italic>p</italic> = 0.21). <xref ref-type="fig" rid="pone.0194525.g001">Fig 1</xref> shows the pathological features of the polyploid DLBCL cases. Consistent with our previous study [<xref rid="pone.0194525.ref011" ref-type="bibr">11</xref>], histological findings of Hodgkin&#x02019;s-like giant cells and multilobated cells were observed in cases of polyploid DLBCL.</p><table-wrap id="pone.0194525.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0194525.t001</object-id><label>Table 1</label><caption><title>Clinical features of polyploid DLBCL and control DLBCL.</title></caption><alternatives><graphic id="pone.0194525.t001g" xlink:href="pone.0194525.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" rowspan="2" colspan="1">Clinical features</th><th align="justify" colspan="2" rowspan="1">Polyploid cases (N = 51)</th><th align="justify" colspan="2" rowspan="1">Control cases (N = 53)</th><th align="justify" rowspan="2" colspan="1"><italic>p</italic>-value</th></tr><tr><th align="justify" rowspan="1" colspan="1">No.</th><th align="justify" rowspan="1" colspan="1">%</th><th align="justify" rowspan="1" colspan="1">No.</th><th align="justify" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age. Years</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Median</td><td align="left" rowspan="1" colspan="1">69</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">72</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Range</td><td align="left" rowspan="1" colspan="1">36&#x02013;84</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">22&#x02013;93</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Male</td><td align="left" rowspan="1" colspan="1">29/51</td><td align="char" char="." rowspan="1" colspan="1">56.9</td><td align="left" rowspan="1" colspan="1">23/53</td><td align="char" char="." rowspan="1" colspan="1">43.4</td><td align="char" char="." rowspan="1" colspan="1">0.17</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Female</td><td align="left" rowspan="1" colspan="1">22/51</td><td align="char" char="." rowspan="1" colspan="1">43.1</td><td align="left" rowspan="1" colspan="1">30/53</td><td align="char" char="." rowspan="1" colspan="1">55.6</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ECOG PS &#x0003e; 1</td><td align="left" rowspan="1" colspan="1">12/51</td><td align="char" char="." rowspan="1" colspan="1">23.5</td><td align="left" rowspan="1" colspan="1">15/53</td><td align="char" char="." rowspan="1" colspan="1">28.3</td><td align="char" char="." rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" rowspan="1" colspan="1">Extranodal infiltration site &#x0003e; 1</td><td align="left" rowspan="1" colspan="1">6/51</td><td align="char" char="." rowspan="1" colspan="1">11.8</td><td align="left" rowspan="1" colspan="1">9/53</td><td align="char" char="." rowspan="1" colspan="1">17.0</td><td align="char" char="." rowspan="1" colspan="1">0.45</td></tr><tr><td align="left" rowspan="1" colspan="1">B symptoms</td><td align="left" rowspan="1" colspan="1">11/51</td><td align="char" char="." rowspan="1" colspan="1">21.6</td><td align="left" rowspan="1" colspan="1">10/53</td><td align="char" char="." rowspan="1" colspan="1">18.9</td><td align="char" char="." rowspan="1" colspan="1">0.73</td></tr><tr><td align="left" rowspan="1" colspan="1">Elevated LDH</td><td align="left" rowspan="1" colspan="1">36/51</td><td align="char" char="." rowspan="1" colspan="1">70.6</td><td align="left" rowspan="1" colspan="1">39/53</td><td align="char" char="." rowspan="1" colspan="1">73.6</td><td align="char" char="." rowspan="1" colspan="1">0.73</td></tr><tr><td align="left" rowspan="1" colspan="1">Ann Arbor Stage &#x0003e; 2</td><td align="left" rowspan="1" colspan="1">36/51</td><td align="char" char="." rowspan="1" colspan="1">70.6</td><td align="left" rowspan="1" colspan="1">36/53</td><td align="char" char="." rowspan="1" colspan="1">67.9</td><td align="char" char="." rowspan="1" colspan="1">0.77</td></tr><tr><td align="left" rowspan="1" colspan="1">IPI score</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Low/Low int</td><td align="left" rowspan="1" colspan="1">24/51</td><td align="char" char="." rowspan="1" colspan="1">47.1</td><td align="left" rowspan="1" colspan="1">19/53</td><td align="char" char="." rowspan="1" colspan="1">35.8</td><td align="char" char="." rowspan="1" colspan="1">0.25</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;High int/High</td><td align="left" rowspan="1" colspan="1">27/51</td><td align="char" char="." rowspan="1" colspan="1">52.9</td><td align="left" rowspan="1" colspan="1">34/53</td><td align="char" char="." rowspan="1" colspan="1">54.2</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Median follow up period<break/>(Months)</td><td align="center" colspan="2" rowspan="1">27 months<break/>(1&#x02013;86 months)</td><td align="center" colspan="2" rowspan="1">37 months<break/>(0.2&#x02013;79.5 months)</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>PS, performance status; LDH, lactate dehydrogenase; IPI, international prognostic index;</p></fn><fn id="t001fn002"><p>Low int, low intermediate risk; High int, high intermediate risk;</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone.0194525.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0194525.t002</object-id><label>Table 2</label><caption><title>Clinical outocomes and therapy of polyploid DLBCL and control DLBCL.</title></caption><alternatives><graphic id="pone.0194525.t002g" xlink:href="pone.0194525.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Clinical features</th><th align="left" colspan="2" rowspan="1">Polyploid cases (N = 51)</th><th align="left" colspan="2" rowspan="1">Control cases (N = 53)</th><th align="left" rowspan="2" colspan="1"><italic>p</italic>-value</th></tr><tr><th align="left" rowspan="1" colspan="1">No.</th><th align="left" rowspan="1" colspan="1">%</th><th align="left" rowspan="1" colspan="1">No.</th><th align="left" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Type of initial therapy</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Chemotherapy</td><td align="left" rowspan="1" colspan="1">48/51</td><td align="char" char="." rowspan="1" colspan="1">94.1</td><td align="left" rowspan="1" colspan="1">46/53</td><td align="char" char="." rowspan="1" colspan="1">86.8</td><td align="char" char="." rowspan="1" colspan="1">0.32<xref ref-type="table-fn" rid="t002fn003">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;R-CHOP/R-CHOP like regimen</td><td align="left" rowspan="1" colspan="1">45/48</td><td align="char" char="." rowspan="1" colspan="1">93.8</td><td align="left" rowspan="1" colspan="1">43/46</td><td align="char" char="." rowspan="1" colspan="1">93.5</td><td align="char" char="." rowspan="1" colspan="1">1.00<xref ref-type="table-fn" rid="t002fn003">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Other</td><td align="left" rowspan="1" colspan="1">3/48</td><td align="char" char="." rowspan="1" colspan="1">6.2</td><td align="left" rowspan="1" colspan="1">3/46</td><td align="char" char="." rowspan="1" colspan="1">6.5</td><td align="char" char="." rowspan="1" colspan="1">1.00<xref ref-type="table-fn" rid="t002fn003">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Radiation therapy</td><td align="left" rowspan="1" colspan="1">10/51</td><td align="char" char="." rowspan="1" colspan="1">19.6</td><td align="left" rowspan="1" colspan="1">9/53</td><td align="char" char="." rowspan="1" colspan="1">17.0</td><td align="char" char="." rowspan="1" colspan="1">0.73</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Radiation therapy only</td><td align="left" rowspan="1" colspan="1">0/10</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">3/9</td><td align="char" char="." rowspan="1" colspan="1">33.3</td><td align="char" char="." rowspan="1" colspan="1">0.24<xref ref-type="table-fn" rid="t002fn003">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No therapy</td><td align="left" rowspan="1" colspan="1">3/51</td><td align="char" char="." rowspan="1" colspan="1">5.9</td><td align="left" rowspan="1" colspan="1">4/53</td><td align="char" char="." rowspan="1" colspan="1">7.5</td><td align="char" char="." rowspan="1" colspan="1">1.00<xref ref-type="table-fn" rid="t002fn003">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Response to initial therapy</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;CR</td><td align="left" rowspan="1" colspan="1">31/48</td><td align="char" char="." rowspan="1" colspan="1">64.6</td><td align="left" rowspan="1" colspan="1">37/49</td><td align="char" char="." rowspan="1" colspan="1">75.5</td><td align="char" char="." rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;PR</td><td align="left" rowspan="1" colspan="1">10/48</td><td align="char" char="." rowspan="1" colspan="1">20.8</td><td align="left" rowspan="1" colspan="1">6/49</td><td align="char" char="." rowspan="1" colspan="1">12.2</td><td align="char" char="." rowspan="1" colspan="1">0.25</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;SD</td><td align="left" rowspan="1" colspan="1">1/48</td><td align="char" char="." rowspan="1" colspan="1">2.1</td><td align="left" rowspan="1" colspan="1">2/49</td><td align="char" char="." rowspan="1" colspan="1">4.1</td><td align="char" char="." rowspan="1" colspan="1">1.00<xref ref-type="table-fn" rid="t002fn003">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;PD</td><td align="left" rowspan="1" colspan="1">6/48</td><td align="char" char="." rowspan="1" colspan="1">12.5</td><td align="left" rowspan="1" colspan="1">4/49</td><td align="char" char="." rowspan="1" colspan="1">8.2.</td><td align="char" char="." rowspan="1" colspan="1">0.52<xref ref-type="table-fn" rid="t002fn003">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Not evaluable</td><td align="left" rowspan="1" colspan="1">3/51</td><td align="char" char="." rowspan="1" colspan="1">5.9</td><td align="left" rowspan="1" colspan="1">4/53</td><td align="char" char="." rowspan="1" colspan="1">7.5</td><td align="char" char="." rowspan="1" colspan="1">1.00<xref ref-type="table-fn" rid="t002fn003">*</xref></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone;</p></fn><fn id="t002fn002"><p>PBSCT, peripheral blood stem cell transplantation; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.</p></fn><fn id="t002fn003"><p>*Fisher&#x02019;s exact test.</p></fn></table-wrap-foot></table-wrap><fig id="pone.0194525.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0194525.g001</object-id><label>Fig 1</label><caption><title>Histology of polyploid diffuse large B-cell lymphoma (DLBCL).</title><p>(A) HE staining, large tumor cells (black arrows). (B) Tumor cells were positive for CD20. (C) HE staining, multilobated tumor cells (black arrows) with many apoptotic cells (arrow heads). (D) Tumor cells were positive for CD20. (E) HE staining, multilobated medium-sized cells (black arrows). (F) Tumor cells were positive for CD20.</p></caption><graphic xlink:href="pone.0194525.g001"/></fig></sec><sec id="sec013"><title>Immunohistochemistry analysis and chromosomal translocation abnormalities</title><p>In order to examine the characteristics of immunohistochemistry analysis and chromosomal translocation abnormalities. The IHC characteristics and chromosomal translocation abnormalities between the two groups are summarized in <xref ref-type="table" rid="pone.0194525.t003">Table 3</xref>. <xref ref-type="fig" rid="pone.0194525.g002">Fig 2</xref> shows the result of IHC in the polyploid DLBCL cases. No significant difference was observed between polyploid DLBCL and control DLBCL cases with respect to the cell of origin according to Hans classification markers (CD10, BCL6, and MUM1) [<xref rid="pone.0194525.ref017" ref-type="bibr">17</xref>] and the other markers (CD5, BCL2, CD30, and EBV-ISH). As shown in <xref ref-type="supplementary-material" rid="pone.0194525.s001">S1 Fig</xref>, there was no significant difference in the proportion of positivity of various markers among CD20-positive tumor cells between the two groups. In addition, there was no significant difference between polyploid DLBCL and control DLBCL cases with respect to the rates of <italic>BCL2</italic>, <italic>BCL6</italic>, and <italic>MYC</italic> translocations, respectively.</p><table-wrap id="pone.0194525.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0194525.t003</object-id><label>Table 3</label><caption><title>Immunohistochemistry analysis and chromosomal translocation abnormalities.</title></caption><alternatives><graphic id="pone.0194525.t003g" xlink:href="pone.0194525.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" rowspan="2" colspan="1"/><th align="justify" colspan="2" rowspan="1">Polyploid cases (N = 51)</th><th align="justify" colspan="2" rowspan="1">Control cases (N = 53)</th><th align="justify" rowspan="2" colspan="1"><italic>p</italic>-value</th></tr><tr><th align="justify" rowspan="1" colspan="1">No.</th><th align="justify" rowspan="1" colspan="1">%</th><th align="justify" rowspan="1" colspan="1">No.</th><th align="justify" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Immunohistochemistry</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;CD5 expression</td><td align="left" rowspan="1" colspan="1">12/51</td><td align="left" rowspan="1" colspan="1">23.5</td><td align="left" rowspan="1" colspan="1">14/53</td><td align="left" rowspan="1" colspan="1">26.4</td><td align="char" char="." rowspan="1" colspan="1">0.73</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;CD10 expression</td><td align="left" rowspan="1" colspan="1">18/51</td><td align="left" rowspan="1" colspan="1">35.3</td><td align="left" rowspan="1" colspan="1">17/53</td><td align="left" rowspan="1" colspan="1">32.1</td><td align="char" char="." rowspan="1" colspan="1">0.73</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;CD20 expression</td><td align="left" rowspan="1" colspan="1">51/51</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">53/53</td><td align="left" rowspan="1" colspan="1">100</td><td align="char" char="." rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;BCL2 expression</td><td align="left" rowspan="1" colspan="1">40/51</td><td align="left" rowspan="1" colspan="1">78.4</td><td align="left" rowspan="1" colspan="1">38/48</td><td align="left" rowspan="1" colspan="1">79.2</td><td align="char" char="." rowspan="1" colspan="1">0.93</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;BCL6 expression</td><td align="left" rowspan="1" colspan="1">38/51</td><td align="left" rowspan="1" colspan="1">74.5</td><td align="left" rowspan="1" colspan="1">31/53</td><td align="left" rowspan="1" colspan="1">58.5</td><td align="char" char="." rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;MUM1 expression</td><td align="left" rowspan="1" colspan="1">36/51</td><td align="left" rowspan="1" colspan="1">70.6</td><td align="left" rowspan="1" colspan="1">39/53</td><td align="left" rowspan="1" colspan="1">73.6</td><td align="char" char="." rowspan="1" colspan="1">0.73</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;CD30 expression</td><td align="left" rowspan="1" colspan="1">6/51</td><td align="left" rowspan="1" colspan="1">11.8</td><td align="left" rowspan="1" colspan="1">6/53</td><td align="left" rowspan="1" colspan="1">11.3</td><td align="char" char="." rowspan="1" colspan="1">0.94</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;EBER positivity</td><td align="left" rowspan="1" colspan="1">2/51</td><td align="left" rowspan="1" colspan="1">3.9</td><td align="left" rowspan="1" colspan="1">5/53</td><td align="left" rowspan="1" colspan="1">9.4</td><td align="char" char="." rowspan="1" colspan="1">0.44<xref ref-type="table-fn" rid="t003fn002">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Cell of origin</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;GCB type</td><td align="left" rowspan="1" colspan="1">23/51</td><td align="left" rowspan="1" colspan="1">41.2</td><td align="left" rowspan="1" colspan="1">19/53</td><td align="left" rowspan="1" colspan="1">35.8</td><td align="char" char="." rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Non-GCB type</td><td align="left" rowspan="1" colspan="1">28/51</td><td align="left" rowspan="1" colspan="1">58.8</td><td align="left" rowspan="1" colspan="1">34/53</td><td align="left" rowspan="1" colspan="1">64.2</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Chromosomal translocation abnormalities</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>BCL2</italic> translocation</td><td align="left" rowspan="1" colspan="1">8/51</td><td align="left" rowspan="1" colspan="1">15.7</td><td align="left" rowspan="1" colspan="1">4/53</td><td align="left" rowspan="1" colspan="1">7.5</td><td align="char" char="." rowspan="1" colspan="1">0.23<xref ref-type="table-fn" rid="t003fn002">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>BCL6</italic> translocation</td><td align="left" rowspan="1" colspan="1">6/51</td><td align="left" rowspan="1" colspan="1">11.8</td><td align="left" rowspan="1" colspan="1">10/53</td><td align="left" rowspan="1" colspan="1">18.9</td><td align="char" char="." rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>MYC</italic> translocation</td><td align="left" rowspan="1" colspan="1">2/51</td><td align="left" rowspan="1" colspan="1">3.9</td><td align="left" rowspan="1" colspan="1">2/53</td><td align="left" rowspan="1" colspan="1">3.8</td><td align="char" char="." rowspan="1" colspan="1">1.00<xref ref-type="table-fn" rid="t003fn002">*</xref></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>GCB, germinal center B-cell-like diffuse large B-cell lymphoma; EBER, EBV-encoded small RNAs</p></fn><fn id="t003fn002"><p>*Fisher&#x02019;s exact test.</p></fn></table-wrap-foot></table-wrap><fig id="pone.0194525.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0194525.g002</object-id><label>Fig 2</label><caption><title>Analysis of immunohistochemistry staining in polyploid DLBCL.</title><p>Tumor cells were positivity in each immunohistochemistry. CD5 (X400), (B) CD10 (X400), (C) CD30 (X400), (D) BCL2 (X400), (E) BCL6 (X400) and (F) MUM1 (X400).</p></caption><graphic xlink:href="pone.0194525.g002"/></fig></sec><sec id="sec014"><title>Clinical follow-up</title><p>We show the OS and PFS of polyploid DLBCL and control DLBCL cases. (<xref ref-type="fig" rid="pone.0194525.g003">Fig 3</xref>) The OS curve was significantly poorer in the polyploid cases than in the control cases (<italic>p</italic> = 0.04). The PFS curves were not significantly different between the polyploid DLBCL and control DLBCL (<italic>p</italic> = 0.49). In addition, we further compared the OS and PFS between the two groups including only cases that received R-CHOP regimens to more effectively investigate the effect of polyploidy on the treatment response. As shown in <xref ref-type="fig" rid="pone.0194525.g004">Fig 4</xref>, OS was significantly poorer in the polyploid cases than in the control cases (<italic>p</italic> = 0.02), whereas there was no difference in PFS between the two groups (<italic>p</italic> = 0.27).</p><fig id="pone.0194525.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0194525.g003</object-id><label>Fig 3</label><caption><title>Overall survival and progression-free survival between polyploid DLBCL, NOS (n = 51) and control DLBCL, NOS (n = 53) patients.</title><p>(A) The overall survival curves were significantly worse for polyploid DLBCL than control DLBCL (<italic>p</italic> = 0.04). (B) The progression-free survival curves were not significantly different between the polyploid DLBCL and control DLBCL (<italic>p</italic> = 0.49).</p></caption><graphic xlink:href="pone.0194525.g003"/></fig><fig id="pone.0194525.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0194525.g004</object-id><label>Fig 4</label><caption><title>Overall survival and progression-free survival between polyploid DLBCL, NOS (n = 45) and control DLBCL, NOS (n = 42) patients in only cases who received R-CHOP regimens.</title><p>(A) The overall survival curves were significantly worse for polyploid DLBCL than control DLBCL (<italic>p</italic> = 0.02). (B) The progression-free survival curves were not significantly different between polyploid DLBCL and control DLBCL (<italic>p</italic> = 0.27).</p></caption><graphic xlink:href="pone.0194525.g004"/></fig></sec><sec id="sec015"><title>Prognostic factors</title><p>We conducted univariate and multivariate analysis to investigate factors related to OS in DLBCL. As shown in <xref ref-type="table" rid="pone.0194525.t004">Table 4</xref>, the univariate analysis revealed the following results: polyploid abnormalities (hazard ratio: HR, 2.19 [95% confidence interval: 95% CI, 0.99&#x02013;4.86], <italic>p</italic> = 0.05), and IPI high int or high risk (HR, 4.32 [95% CI, 1.47&#x02013;12.74], <italic>p</italic> = 0.008). The multivariate analysis indicated that polyploid abnormality (HR, 3.11 [95% CI, 1.27&#x02013;7.66], <italic>p</italic> = 0.01) was an independent poor prognostic factor of OS.</p><table-wrap id="pone.0194525.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0194525.t004</object-id><label>Table 4</label><caption><title>Univariate and multivariate analysis for overall survival in DLBCL.</title></caption><alternatives><graphic id="pone.0194525.t004g" xlink:href="pone.0194525.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" rowspan="1" colspan="1"/><th align="justify" rowspan="1" colspan="1">Parameters</th><th align="justify" rowspan="1" colspan="1">Hazard ratio<break/>[95% confidence interval]</th><th align="justify" rowspan="1" colspan="1"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Univariate analysis</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Polyploid abnormalities</td><td align="left" rowspan="1" colspan="1">2.19 [0.99&#x02013;4.86]</td><td align="char" char="." rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">B symptoms</td><td align="left" rowspan="1" colspan="1">1.53 [0.65&#x02013;3.59]</td><td align="char" char="." rowspan="1" colspan="1">0.33</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CD5 expression</td><td align="left" rowspan="1" colspan="1">1.49 [0.67&#x02013;3.30]</td><td align="char" char="." rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BCL2 expression</td><td align="left" rowspan="1" colspan="1">1.66 [0.68&#x02013;4.08]</td><td align="char" char="." rowspan="1" colspan="1">0.27</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IPI high int or high risk</td><td align="left" rowspan="1" colspan="1">4.32 [1.47&#x02013;12.74]</td><td align="char" char="." rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Non-GCB subtype</td><td align="left" rowspan="1" colspan="1">1.45 [0.64&#x02013;3.30]</td><td align="char" char="." rowspan="1" colspan="1">0.37</td></tr><tr><td align="left" rowspan="1" colspan="1">Multivariate analysis</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IPI high int or high risk</td><td align="left" rowspan="1" colspan="1">5.36 [1.80&#x02013;15.92]</td><td align="char" char="." rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Polyploid abnormalities</td><td align="left" rowspan="1" colspan="1">3.11 [1.27&#x02013;7.66]</td><td align="char" char="." rowspan="1" colspan="1">0.01</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t004fn001"><p>IPI, International Prognostic Index; GCB, Germinal center B-cell-like diffuse large B-cell lymphoma.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="conclusions" id="sec016"><title>Discussion</title><p>In our previous study, we found unique pathological features of patients with polyploid DLBCL, presenting a greater number of huge and multinucleated cells compared to those of the control group (DLBCL without polyploidy) [<xref rid="pone.0194525.ref011" ref-type="bibr">11</xref>]. In the current study, we demonstrated that polyploid DLBCL represents a poor prognostic factor, with a reduction in OS and emerging as an independent factor contributing to poor prognosis in multivariate analysis.</p><p>Abnormalities of <italic>p53</italic> have been reported to cause polyploid chromosomal abnormalities [<xref rid="pone.0194525.ref018" ref-type="bibr">18</xref>,<xref rid="pone.0194525.ref019" ref-type="bibr">19</xref>]. Tetraploidization promotes tumor formation in the mammary gland epithelial cells of mice with non-functional <italic>p53</italic>, and it is believed that <italic>p53</italic> gene abnormalities play an important role in the formation of polyploid chromosomal abnormalities [<xref rid="pone.0194525.ref005" ref-type="bibr">5</xref>]. A previous study has demonstrated that immunostaining of p53 (&#x0003e;50% positive in tumor cells) is useful as an alternative means to predict the mutation of <italic>p53</italic> in DLBCL [<xref rid="pone.0194525.ref020" ref-type="bibr">20</xref>]. In our study, 81.8% (27/33) of polyploid DLBCL cases tested positive for p53 in the immunohistochemistry analysis. Although the cut off (&#x0003e;30% positive in tumor cells) was different among the various studies, 38.4%&#x02013;48.4% of DLBCL cases [<xref rid="pone.0194525.ref021" ref-type="bibr">21</xref>&#x02013;<xref rid="pone.0194525.ref023" ref-type="bibr">23</xref>] have been reported to test positive for p53. Compared with these previous reports, more p53-positive polyploid DLBCL cases were found in the current study. However, in our study, mutation analysis of <italic>p53</italic> was not performed, and the number of cases with a confirmed <italic>p53</italic> mutation is unknown. Together, these results indicate that mutation of <italic>p53</italic> may play an important role in the formation of polyploid chromosomal abnormalities in polyploid DLBCL.</p><p>In our study, polyploid DLBCL was associated with a significantly worse overall survival only in cases who received R-CHOP regimens. This might be attributed to drug resistance. In a previous study using a colon cancer cell line, tetraploid cells were found to be associated with drug resistance caused by chromosomal instability [<xref rid="pone.0194525.ref024" ref-type="bibr">24</xref>]. It was reported that there is an association between chromosomal instability and intratumor genetic heterogeneity in gastric cancer and colorectal cancer with aneuploidy, including polyploidy [<xref rid="pone.0194525.ref025" ref-type="bibr">25</xref>,<xref rid="pone.0194525.ref026" ref-type="bibr">26</xref>]. Intratumor genetic heterogeneity may play a role in drug resistance [<xref rid="pone.0194525.ref027" ref-type="bibr">27</xref>,<xref rid="pone.0194525.ref028" ref-type="bibr">28</xref>]. By using array CGH, intratumor genetic heterogeneity was detected in DLBCL, adult T-cell leukemia/lymphoma, mantle cell lymphoma, and peripheral T-cell lymphoma, and all of these malignant lymphomas with intratumor genetic heterogeneity were resistant to treatment [<xref rid="pone.0194525.ref029" ref-type="bibr">29</xref>,<xref rid="pone.0194525.ref030" ref-type="bibr">30</xref>]. Based on these results, we hypothesize that poorer OS in polyploid DLBCL is caused by drug resistance thorough chromosomal instability and intratumor genetic heterogeneity; however, more detailed research is necessary to validate our speculation.</p><p>In the multivariate analysis, polyploid chromosomal abnormality was found to be an independent poor prognostic factor. Generally, solid tumors (including esophagus carcinoma, and ovarian carcinoma) with polyploid chromosomal abnormalities have a poor prognosis [<xref rid="pone.0194525.ref031" ref-type="bibr">31</xref>,<xref rid="pone.0194525.ref032" ref-type="bibr">32</xref>]. Chromosomal instability resulting from ongoing numerical and structural chromosomal aberrations might be responsible for this effect [<xref rid="pone.0194525.ref031" ref-type="bibr">31</xref>,<xref rid="pone.0194525.ref032" ref-type="bibr">32</xref>]. Further, there are reports that the complex karyotypes that can be detected with G-banding are related to chromosomal instability [<xref rid="pone.0194525.ref033" ref-type="bibr">33</xref>,<xref rid="pone.0194525.ref034" ref-type="bibr">34</xref>]. Chromosomal instability in solid tumors is strongly correlated with progression to high-grade transformation and is generally considered a poor prognostic factor [<xref rid="pone.0194525.ref035" ref-type="bibr">35</xref>]. In a study of colon cancer, long-term culture and examination of stable diploid progenitors by using isogenic tetraploid cells showed that chromosomal instability was induced after polyploidization (genome-doubling), and polyploid abnormalities were caused at a comparatively early stage in the examination [<xref rid="pone.0194525.ref036" ref-type="bibr">36</xref>]. These findings suggest a close relationship between polyploid chromosomal abnormalities and chromosomal instability, indicating that polyploidy may cause poor prognosis in DLBCL cases.</p><p>This study has some limitations. The cases in the current study were classified into polyploid cases and cases without polyploidy by using G-banding. The karyotypes were not necessarily obtained for all cases with G-banding for various reasons, including the status of the lymphoma cells and quality of tissue samples. Therefore, the possibility of some bias in case selection cannot be excluded. Nonetheless, the G-banding technique is highly versatile and is widely used in the diagnosis of hematopoietic tumors. As such, the detection of polyploid abnormalities in a G-band examination is a useful tool in prognosis. Detailed genetic examination in the future should be performed to ascertain the results in this study.</p><p>In conclusion, polyploid chromosomal abnormality was associated with poor OS and was an independent poor prognostic factor. The detection of polyploid DLBCL by using G-banding might represent a new prognostic factor of poor OS.</p></sec><sec sec-type="supplementary-material" id="sec017"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0194525.s001"><label>S1 Fig</label><caption><title>Quantification of various markers in CD20-positive tumor cells.</title><p>CD5, (B)CD10, (C)CD30, (D)BCL2, (E)BCL6, (F)MUM1. There was no significant difference in the proportion of positivity of various markers in CD20-positive tumor cells between the two groups.</p><p>(TIF)</p></caption><media xlink:href="pone.0194525.s001.TIF"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0194525.s002"><label>S1 File</label><caption><title>Clinical data in this study.</title><p>(XLSX)</p></caption><media xlink:href="pone.0194525.s002.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0194525.s003"><label>S1 Table</label><caption><title>Karyotype of polyploid DLBCL.</title><p>(DOCX)</p></caption><media xlink:href="pone.0194525.s003.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0194525.s004"><label>S2 Table</label><caption><title>Karyotype of control DLBCL.</title><p>(DOCX)</p></caption><media xlink:href="pone.0194525.s004.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0194525.s005"><label>S3 Table</label><caption><title>Antibodies used for flow cytometric immunophenotyping analysis and immunohistochemical staining analysis.</title><p>(DOCX)</p></caption><media xlink:href="pone.0194525.s005.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The outstanding technical assistance of Fumiko Arakawa, Mayumi Miura and Kazutaka Nakashima is very much appreciated.</p></ack><ref-list><title>References</title><ref id="pone.0194525.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Coiffer</surname><given-names>B</given-names></name> (<year>2001</year>). <article-title>Diffuse large cell lymphoma</article-title>. <source><italic>Curr Opin Oncol</italic></source>
<volume>13</volume>:<fpage>325</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="pmid">11555708</pub-id></mixed-citation></ref><ref id="pone.0194525.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Rossi</surname><given-names>D</given-names></name>, <name><surname>Gaidano</surname><given-names>G</given-names></name> (<year>2002</year>). <article-title>Molecular heterogeneity of diffuse large B-cell Lymphoma: implications for disease management and prognosis</article-title>. <source><italic>Hematology</italic></source>
<volume>7</volume>:<fpage>239</fpage>&#x02013;<lpage>52</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/1024533021000024058">10.1080/1024533021000024058</ext-link></comment>
<pub-id pub-id-type="pmid">14972786</pub-id></mixed-citation></ref><ref id="pone.0194525.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Nitsu</surname><given-names>N</given-names></name>, <name><surname>Okamoto</surname><given-names>M</given-names></name>, <name><surname>Miura</surname><given-names>I</given-names></name>, <name><surname>Hirano</surname><given-names>M</given-names></name> (<year>2009</year>). <article-title>Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphoma</article-title>. <source><italic>Cancer Sci</italic></source>
<volume>100</volume>:<fpage>233</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1349-7006.2008.01035.x">10.1111/j.1349-7006.2008.01035.x</ext-link></comment>
<pub-id pub-id-type="pmid">19038003</pub-id></mixed-citation></ref><ref id="pone.0194525.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Horn</surname><given-names>H</given-names></name>, <name><surname>Ziepert</surname><given-names>M</given-names></name>, <name><surname>Wartenberg</surname><given-names>M</given-names></name>, <name><surname>Staiger</surname><given-names>AM</given-names></name>, <name><surname>Barth</surname><given-names>TF</given-names></name>, <name><surname>Bernd</surname><given-names>HW</given-names></name>
<etal>et al</etal> (<year>2015</year>). <article-title>Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma</article-title>. <source><italic>Leukemia</italic></source>
<volume>29</volume>:<fpage>1564</fpage>&#x02013;<lpage>70</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/leu.2015.43">10.1038/leu.2015.43</ext-link></comment>
<pub-id pub-id-type="pmid">25687653</pub-id></mixed-citation></ref><ref id="pone.0194525.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Shi</surname><given-names>Q</given-names></name>, <name><surname>King</surname><given-names>RW</given-names></name> (<year>2005</year>). <article-title>Chromosome nondisjunction yields tetraploid rather than aneupolid in human cell lines</article-title>. <source><italic>Nature</italic></source>
<volume>437</volume>:<fpage>1038</fpage>&#x02013;<lpage>42</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature03958">10.1038/nature03958</ext-link></comment>
<pub-id pub-id-type="pmid">16222248</pub-id></mixed-citation></ref><ref id="pone.0194525.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Davaadelger</surname><given-names>B</given-names></name>, <name><surname>Shen</surname><given-names>H</given-names></name>, <name><surname>Maki</surname><given-names>CG</given-names></name> (<year>2014</year>). <article-title>Novel roles for p53 in the genesis and targeting of tetraploid cancer cells</article-title>. <source><italic>PLos One</italic></source>
<volume>9</volume>:<fpage>e110844</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0110844">10.1371/journal.pone.0110844</ext-link></comment>
<pub-id pub-id-type="pmid">25380055</pub-id></mixed-citation></ref><ref id="pone.0194525.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Pinto</surname><given-names>AE</given-names></name>, <name><surname>Pereira</surname><given-names>T</given-names></name>, <name><surname>Santos</surname><given-names>M</given-names></name>, <name><surname>Branco</surname><given-names>M</given-names></name>, <name><surname>Dias</surname><given-names>A</given-names></name>, <name><surname>Silva</surname><given-names>GL</given-names></name>
<etal>et al</etal> (<year>2013</year>). <article-title>DNA ploidy is an independent predictor of survival in breast invasive ductal carcinoma: a long-term multivariate analysis of 393 patients</article-title>. <source><italic>Ann Surg Oncol</italic></source>
<volume>20</volume>:<fpage>1530</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1245/s10434-012-2804-6">10.1245/s10434-012-2804-6</ext-link></comment>
<pub-id pub-id-type="pmid">23250736</pub-id></mixed-citation></ref><ref id="pone.0194525.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Carter</surname><given-names>SL</given-names></name>, <name><surname>Cibulskis</surname><given-names>K</given-names></name>, <name><surname>Helman</surname><given-names>E</given-names></name>, <name><surname>McKenna</surname><given-names>A</given-names></name>, <name><surname>Shen</surname><given-names>H</given-names></name>, <name><surname>Zack</surname><given-names>T</given-names></name>
<etal>et al</etal> (<year>2012</year>). <article-title>Absolute quantification of somatic DNA alterations in human cancer</article-title>. <source><italic>Nat Biotechnol</italic></source>
<volume>30</volume>:<fpage>413</fpage>&#x02013;<lpage>21</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nbt.2203">10.1038/nbt.2203</ext-link></comment>
<pub-id pub-id-type="pmid">22544022</pub-id></mixed-citation></ref><ref id="pone.0194525.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Araujo</surname><given-names>SE</given-names></name>, <name><surname>Bermardo</surname><given-names>WM</given-names></name>, <name><surname>Habr-Gama</surname><given-names>A</given-names></name>, <name><surname>Kiss</surname><given-names>DR</given-names></name>, <name><surname>Cecconello</surname><given-names>l</given-names></name> (<year>2007</year>). <article-title>DNA ploidy status and prognosis in colorectal cancer: a meta-analysis of published data</article-title>. <source><italic>Dis Colon Rectum</italic></source>
<volume>50</volume>:<fpage>1800</fpage>&#x02013;<lpage>10</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s10350-007-9013-6">10.1007/s10350-007-9013-6</ext-link></comment>
<pub-id pub-id-type="pmid">17874166</pub-id></mixed-citation></ref><ref id="pone.0194525.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>L</given-names></name>, <name><surname>Wang</surname><given-names>SA</given-names></name>, <name><surname>DiNardo</surname><given-names>C</given-names></name>, <name><surname>Li</surname><given-names>S</given-names></name>, <name><surname>Hu</surname><given-names>S</given-names></name>, <name><surname>Xu</surname><given-names>J</given-names></name>
<etal>et al</etal> (<year>2017</year>). <article-title>Tetraploidy/near-tetraploidy acute myeloid leukemia</article-title>. <source>Leuk Res</source>
<volume>53</volume>:<fpage>20</fpage>&#x02013;<lpage>27</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.leukres.2016.11.016">10.1016/j.leukres.2016.11.016</ext-link></comment>
<pub-id pub-id-type="pmid">27951415</pub-id></mixed-citation></ref><ref id="pone.0194525.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Shimono</surname><given-names>J</given-names></name>, <name><surname>Miyoshi</surname><given-names>H</given-names></name>, <name><surname>Seto</surname><given-names>M</given-names></name>, <name><surname>Teshima</surname><given-names>T</given-names></name>, <name><surname>Ohshima</surname><given-names>K</given-names></name> (<year>2017</year>). <article-title>Clinical features of diffuse large B-cell lymphoma with polyploidy</article-title>. <source><italic>Pathol int</italic></source>
<volume>67</volume>: <fpage>17</fpage>&#x02013;<lpage>23</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/pin.12478">10.1111/pin.12478</ext-link></comment>
<pub-id pub-id-type="pmid">27868293</pub-id></mixed-citation></ref><ref id="pone.0194525.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Kiyasu</surname><given-names>J</given-names></name>, <name><surname>Miyoshi</surname><given-names>H</given-names></name>, <name><surname>Hirata</surname><given-names>A</given-names></name>, <name><surname>Arakawa</surname><given-names>F</given-names></name>, <name><surname>Ichikawa</surname><given-names>A</given-names></name>, <name><surname>Niino</surname><given-names>D</given-names></name>
<etal>et al</etal> (<year>2015</year>). <article-title>Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma</article-title>. <source><italic>Blood</italic></source>
<volume>126</volume>:<fpage>2193</fpage>&#x02013;<lpage>201</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2015-02-629600">10.1182/blood-2015-02-629600</ext-link></comment>
<pub-id pub-id-type="pmid">26239088</pub-id></mixed-citation></ref><ref id="pone.0194525.ref013"><label>13</label><mixed-citation publication-type="book"><name><surname>Swerdlow</surname><given-names>S</given-names></name>, <name><surname>Campo</surname><given-names>E</given-names></name>, <name><surname>Harris</surname><given-names>N</given-names></name>
<etal>et al</etal>, eds (<year>2008</year>). <source><italic>Who classification of tumors of haematopoietic and lymphoid tissue</italic></source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>IARC</publisher-name>.</mixed-citation></ref><ref id="pone.0194525.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Xu-Monette</surname><given-names>ZY</given-names></name>, <name><surname>Wu</surname><given-names>L</given-names></name>, <name><surname>Visco</surname><given-names>C</given-names></name>, <name><surname>Tai</surname><given-names>YC</given-names></name>, <name><surname>Tzankov</surname><given-names>A</given-names></name>, <name><surname>Liu</surname><given-names>WM</given-names></name>
<etal>et al</etal> (<year>2012</year>). <article-title>Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study</article-title>. <source><italic>Blood</italic></source>
<volume>120</volume>:<fpage>3986</fpage>&#x02013;<lpage>96</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2012-05-433334">10.1182/blood-2012-05-433334</ext-link></comment>
<pub-id pub-id-type="pmid">22955915</pub-id></mixed-citation></ref><ref id="pone.0194525.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Yoshida</surname><given-names>M</given-names></name>, <name><surname>Ichikawa</surname><given-names>A</given-names></name>, <name><surname>Miyoshi</surname><given-names>H</given-names></name>, <name><surname>Takeuchi</surname><given-names>M</given-names></name>, <name><surname>Kimura</surname><given-names>Y</given-names></name>, <name><surname>Nino</surname><given-names>D</given-names></name>
<etal>et al</etal> (<year>2012</year>). <article-title>High frequency of t(14;18) in Hodgkin&#x02019;s lymphoma associated with follicular lymphoma</article-title>. <source>Pathol int</source>
<volume>62</volume>:<fpage>518</fpage>&#x02013;<lpage>24</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1440-1827.2012.02835.x">10.1111/j.1440-1827.2012.02835.x</ext-link></comment>
<pub-id pub-id-type="pmid">22827759</pub-id></mixed-citation></ref><ref id="pone.0194525.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Yoshida</surname><given-names>M</given-names></name>, <name><surname>Ichikawa</surname><given-names>A</given-names></name>, <name><surname>Miyoshi</surname><given-names>H</given-names></name>, <name><surname>Kiyasu</surname><given-names>J</given-names></name>, <name><surname>Kimura</surname><given-names>Y</given-names></name>, <name><surname>Arakawa</surname><given-names>F</given-names></name>
<etal>et al</etal> (<year>2015</year>). <article-title>Clinicopathological features of double-hit B-cell lymphomas with MYC and BCL2, BCL6 or CCND1 rearrangements</article-title>. <source>Pathol int</source>
<volume>65</volume>:<fpage>519</fpage>&#x02013;<lpage>27</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/pin.12335">10.1111/pin.12335</ext-link></comment>
<pub-id pub-id-type="pmid">26224092</pub-id></mixed-citation></ref><ref id="pone.0194525.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Hans</surname><given-names>CP</given-names></name>, <name><surname>Weisenburger</surname><given-names>DD</given-names></name>, <name><surname>Greiner</surname><given-names>TC</given-names></name>, <name><surname>Gascoyne</surname><given-names>RD</given-names></name>, <name><surname>Delabie</surname><given-names>J</given-names></name>, <name><surname>Ott</surname><given-names>G</given-names></name>
<etal>et al</etal> (<year>2004</year>). <article-title>Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray</article-title>. <source><italic>Blood</italic></source>
<volume>103</volume>:<fpage>275</fpage>&#x02013;<lpage>282</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2003-05-1545">10.1182/blood-2003-05-1545</ext-link></comment>
<pub-id pub-id-type="pmid">14504078</pub-id></mixed-citation></ref><ref id="pone.0194525.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Pantic</surname><given-names>M</given-names></name>, <name><surname>Zimmermann</surname><given-names>S</given-names></name>, <name><surname>El Daly</surname><given-names>H</given-names></name>, <name><surname>Optiz</surname><given-names>OG</given-names></name>, <name><surname>Popp</surname><given-names>S</given-names></name>, <name><surname>Boukamp</surname><given-names>P</given-names></name>
<etal>et al</etal> (<year>2006</year>). <article-title>Telomere dysfunction and loss of p53 cooperate in defective mitotic segregation of chromosomes in cancer cells</article-title>. <source><italic>Oncogene</italic></source>
<volume>25</volume>:<fpage>4413</fpage>&#x02013;<lpage>20</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/sj.onc.1209486">10.1038/sj.onc.1209486</ext-link></comment>
<pub-id pub-id-type="pmid">16547498</pub-id></mixed-citation></ref><ref id="pone.0194525.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Spruck</surname><given-names>CH</given-names></name>, <name><surname>Won</surname><given-names>KA</given-names></name>, <name><surname>Reed</surname><given-names>Sl</given-names></name> (<year>1999</year>). <article-title>Deregulated cyclin E induces chromosome instability</article-title>. <source><italic>Nature</italic></source>
<volume>401</volume>:<fpage>297</fpage>&#x02013;<lpage>300</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/45836">10.1038/45836</ext-link></comment>
<pub-id pub-id-type="pmid">10499591</pub-id></mixed-citation></ref><ref id="pone.0194525.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Xu-Monette</surname><given-names>ZY</given-names></name>, <name><surname>Wu</surname><given-names>L</given-names></name>, <name><surname>Visco</surname><given-names>C</given-names></name>, <name><surname>Tai</surname><given-names>YC</given-names></name>, <name><surname>Tzankov</surname><given-names>A</given-names></name>, <name><surname>Liu</surname><given-names>WM</given-names></name>
<etal>et al</etal> (<year>2012</year>). <article-title>Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study</article-title>. <source>Blood</source>
<volume>120</volume>:<fpage>3986</fpage>&#x02013;<lpage>96</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2012-05-433334">10.1182/blood-2012-05-433334</ext-link></comment>
<pub-id pub-id-type="pmid">22955915</pub-id></mixed-citation></ref><ref id="pone.0194525.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>YY</given-names></name>, <name><surname>Yao</surname><given-names>SN</given-names></name>, <name><surname>Zhao</surname><given-names>ZH</given-names></name>, <name><surname>Ma</surname><given-names>J</given-names></name>, <name><surname>Xia</surname><given-names>QX</given-names></name>, <name><surname>Fu</surname><given-names>K</given-names></name>
<etal>et al</etal> (<year>2010</year>). <article-title>PTEN tumor suppressor plays less prognostic role than P53 tumor suppressor in diffuse large B-cell lymphoma</article-title>. <source>Leuk Lymphoma</source>
<volume>51</volume>:<fpage>1692</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3109/10428194.2010.502584">10.3109/10428194.2010.502584</ext-link></comment>
<pub-id pub-id-type="pmid">20807096</pub-id></mixed-citation></ref><ref id="pone.0194525.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Xu-Monette</surname><given-names>ZY</given-names></name>, <name><surname>Moller</surname><given-names>MB</given-names></name>, <name><surname>Tzankov</surname><given-names>A</given-names></name>, <name><surname>Montes-Moreno</surname><given-names>S</given-names></name>, <name><surname>Hu</surname><given-names>W</given-names></name>, <name><surname>manyam</surname><given-names>GC</given-names></name>
<etal>et al</etal> (<year>2013</year>). <article-title>MDM2 phenotypic and genotypic profiling, respective to TP 53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: areport from the International DLBCL Rituximab-CHOP Consortium Program</article-title>. <source>Blood</source>
<volume>122</volume>:<fpage>2630</fpage>&#x02013;<lpage>40</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2012-12-473702">10.1182/blood-2012-12-473702</ext-link></comment>
<pub-id pub-id-type="pmid">23982177</pub-id></mixed-citation></ref><ref id="pone.0194525.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Xie</surname><given-names>Y</given-names></name>, <name><surname>Bulbul</surname><given-names>MA</given-names></name>, <name><surname>Ji</surname><given-names>L</given-names></name>, <name><surname>Inouye</surname><given-names>CM</given-names></name>, <name><surname>Groshen</surname><given-names>SG</given-names></name>, <name><surname>Tulpule</surname><given-names>A</given-names></name>
<etal>et al</etal> (<year>2014</year>). <article-title>p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study</article-title>. <source>Am J Clin Pathol</source>
<volume>141</volume>:<fpage>593</fpage>&#x02013;<lpage>604</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1309/AJCPPHMZ6VHF0WQV">10.1309/AJCPPHMZ6VHF0WQV</ext-link></comment>
<pub-id pub-id-type="pmid">24619762</pub-id></mixed-citation></ref><ref id="pone.0194525.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>AJ</given-names></name>, <name><surname>Endesfelder</surname><given-names>D</given-names></name>, <name><surname>Rowan</surname><given-names>AJ</given-names></name>, <name><surname>Walther</surname><given-names>A</given-names></name>, <name><surname>Birkbak</surname><given-names>NJ</given-names></name>, <name><surname>Futreal</surname><given-names>PA</given-names></name>
<etal>et al</etal> (<year>2011</year>). <article-title>Chromosomal instability confers intrinsic multidrug resistance</article-title>. <source><italic>Cancer Res</italic></source>
<volume>71</volume>:<fpage>1858</fpage>&#x02013;<lpage>70</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1158/0008-5472.CAN-10-3604">10.1158/0008-5472.CAN-10-3604</ext-link></comment>
<pub-id pub-id-type="pmid">21363922</pub-id></mixed-citation></ref><ref id="pone.0194525.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Furuya</surname><given-names>T</given-names></name>, <name><surname>Uchiyama</surname><given-names>T</given-names></name>, <name><surname>Murakami</surname><given-names>T</given-names></name>, <name><surname>Adachi</surname><given-names>A</given-names></name>, <name><surname>Kawauchi</surname><given-names>S</given-names></name>, <name><surname>Oga</surname><given-names>A</given-names></name>
<etal>et al</etal> (<year>2000</year>). <article-title>Relationship between Choromosomal Instability and Intratumoral Regional DNA Ploidy Hetergeneity in Primary Gastric Cancers</article-title>. <source><italic>Clin Cancer Res</italic></source>
<volume>6</volume>:<fpage>2815</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="pmid">10914729</pub-id></mixed-citation></ref><ref id="pone.0194525.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Miyazaki</surname><given-names>Y</given-names></name>, <name><surname>Furuya</surname><given-names>T</given-names></name>, <name><surname>Shiraki</surname><given-names>A</given-names></name>, <name><surname>Sato</surname><given-names>T</given-names></name>, <name><surname>Oga</surname><given-names>A</given-names></name>, <name><surname>Sasaki</surname><given-names>K</given-names></name> (<year>1999</year>). <article-title>The relationship of DNA Ploidy to Chromosomal Instability in Primary Human Colorectal Cancers</article-title>. <source><italic>Cancer Res</italic></source>
<volume>59</volume>:<fpage>5283</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="pmid">10537310</pub-id></mixed-citation></ref><ref id="pone.0194525.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>McGranahan</surname><given-names>N</given-names></name>, <name><surname>Swanton</surname><given-names>C</given-names></name> (<year>2015</year>). <article-title>Biological and therapeutic impact of intracellular heterogeneity in cancer evolution</article-title>. <source><italic>Cancer cell</italic></source>
<volume>27</volume>:<fpage>15</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="pmid">25584892</pub-id></mixed-citation></ref><ref id="pone.0194525.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>McGranahan</surname><given-names>N</given-names></name>, <name><surname>Burrell</surname><given-names>RA</given-names></name>, <name><surname>Endesfelder</surname><given-names>D</given-names></name>, <name><surname>Novelli</surname><given-names>MR</given-names></name>, <name><surname>Swanton</surname><given-names>C</given-names></name> (<year>2012</year>). <article-title>Cancer chromosomal instability: therapeutic and diagnostic challenges</article-title>. <source><italic>EMBO Rep</italic></source>
<volume>13</volume>:<fpage>528</fpage>&#x02013;<lpage>38</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/embor.2012.61">10.1038/embor.2012.61</ext-link></comment>
<pub-id pub-id-type="pmid">22595889</pub-id></mixed-citation></ref><ref id="pone.0194525.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Umino</surname><given-names>A</given-names></name>, <name><surname>Nakagawa</surname><given-names>M</given-names></name>, <name><surname>Utsunomiya</surname><given-names>A</given-names></name>, <name><surname>Tsukasaki</surname><given-names>K</given-names></name>, <name><surname>Taira</surname><given-names>N</given-names></name>, <name><surname>Katayama</surname><given-names>N</given-names></name>
<etal>et al</etal> (<year>2011</year>). <article-title>Clonal evolution of adult T-cell leukemia/lymphoma takes place in the lymph nodes</article-title>. <source><italic>Blood</italic></source>
<volume>117</volume>:<fpage>5473</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2010-12-327791">10.1182/blood-2010-12-327791</ext-link></comment>
<pub-id pub-id-type="pmid">21447829</pub-id></mixed-citation></ref><ref id="pone.0194525.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Suguro</surname><given-names>M</given-names></name>, <name><surname>Yoshida</surname><given-names>N</given-names></name>, <name><surname>Umino</surname><given-names>A</given-names></name>, <name><surname>Kato</surname><given-names>H</given-names></name>, <name><surname>Tagawa</surname><given-names>H</given-names></name>, <name><surname>Nakgawa</surname><given-names>M</given-names></name>
<etal>et al</etal> (<year>2014</year>). <article-title>Clonal heterogeneity of lymphoid malignancies correlates with poor prognosis</article-title>. <source><italic>Cancer Sci</italic></source>
<volume>105</volume>:<fpage>897</fpage>&#x02013;<lpage>904</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/cas.12442">10.1111/cas.12442</ext-link></comment>
<pub-id pub-id-type="pmid">24815991</pub-id></mixed-citation></ref><ref id="pone.0194525.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Storchova</surname><given-names>Z</given-names></name>, <name><surname>Pellman</surname><given-names>D</given-names></name> (<year>2004</year>). <article-title>From polyploidy to aneuploidy, genome instability and cancer</article-title>. <source><italic>Nat Rev Mol Cell Biol</italic></source>
<volume>5</volume>:<fpage>45</fpage>&#x02013;<lpage>54</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrm1276">10.1038/nrm1276</ext-link></comment>
<pub-id pub-id-type="pmid">14708009</pub-id></mixed-citation></ref><ref id="pone.0194525.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Tl</surname><given-names>Zack</given-names></name>, <name><surname>Schumacher</surname><given-names>SE</given-names></name>, <name><surname>Carter</surname><given-names>S</given-names></name>, <name><surname>Cherniack</surname><given-names>AD</given-names></name>, <name><surname>Saksena</surname><given-names>G</given-names></name>, <name><surname>Tabak</surname><given-names>B</given-names></name>
<etal>et al</etal> (<year>2013</year>). <article-title>Pan-cancer patterns of somatic copy number alteration</article-title>. <source><italic>Nat Genet</italic></source>
<volume>45</volume>:<fpage>1134</fpage>&#x02013;<lpage>40</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ng.2760">10.1038/ng.2760</ext-link></comment>
<pub-id pub-id-type="pmid">24071852</pub-id></mixed-citation></ref><ref id="pone.0194525.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Falzetti</surname><given-names>D</given-names></name>, <name><surname>Crescenzi</surname><given-names>B</given-names></name>, <name><surname>Matteuci</surname><given-names>C</given-names></name>, <name><surname>Falini</surname><given-names>B</given-names></name>, <name><surname>Martelli</surname><given-names>MF</given-names></name>, <name><surname>Van Den Berghe</surname><given-names>H</given-names></name>
<etal>et al</etal> (<year>1999</year>). <article-title>Genomic instability and recurrent breakpoints are main cytogenetic findings in Hodgkin&#x02019;s disease</article-title>. <source><italic>Haematologica</italic></source>
<volume>84</volume>:<fpage>298</fpage>&#x02013;<lpage>305</lpage>. <pub-id pub-id-type="pmid">10190942</pub-id></mixed-citation></ref><ref id="pone.0194525.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Sawyer</surname><given-names>JR</given-names></name>, <name><surname>Tricot</surname><given-names>G</given-names></name>, <name><surname>Lukacs</surname><given-names>JL</given-names></name>, <name><surname>Binz</surname><given-names>RL</given-names></name>, <name><surname>Tian</surname><given-names>E</given-names></name>, <name><surname>Barlogie</surname><given-names>B</given-names></name>
<etal>et al</etal> (<year>2005</year>). <article-title>Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q</article-title>. <source><italic>Genes Chromosomes cancer</italic></source>
<volume>42</volume>:<fpage>95</fpage>&#x02013;<lpage>106</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/gcc.20109">10.1002/gcc.20109</ext-link></comment>
<pub-id pub-id-type="pmid">15472896</pub-id></mixed-citation></ref><ref id="pone.0194525.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Lipinski</surname><given-names>KA</given-names></name>, <name><surname>Barber</surname><given-names>LJ</given-names></name>, <name><surname>Davies</surname><given-names>MN</given-names></name>, <name><surname>Ashenden</surname><given-names>M</given-names></name>, <name><surname>Sottoriva</surname><given-names>A</given-names></name>, <name><surname>Gerlinger</surname><given-names>M</given-names></name> (<year>2016</year>). <article-title>Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine</article-title>. <source><italic>Trends Cancer</italic></source>
<volume>2</volume>:<fpage>49</fpage>&#x02013;<lpage>63</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.trecan.2015.11.003">10.1016/j.trecan.2015.11.003</ext-link></comment>
<pub-id pub-id-type="pmid">26949746</pub-id></mixed-citation></ref><ref id="pone.0194525.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Dewhurst</surname><given-names>SM</given-names></name>, <name><surname>McGranahan</surname><given-names>N</given-names></name>, <name><surname>Burrell</surname><given-names>RA</given-names></name>, <name><surname>Rowan</surname><given-names>AJ</given-names></name>, <name><surname>Gronroos</surname><given-names>E</given-names></name>, <name><surname>Endesfelder</surname><given-names>D</given-names></name>
<etal>et al</etal> (<year>2014</year>). <article-title>Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution</article-title>. <source><italic>Cancer Discov</italic></source>
<volume>4</volume>:<fpage>175</fpage>&#x02013;<lpage>85</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1158/2159-8290.CD-13-0285">10.1158/2159-8290.CD-13-0285</ext-link></comment>
<pub-id pub-id-type="pmid">24436049</pub-id></mixed-citation></ref></ref-list></back></article>